---
title: "Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290883269.md"
description: "Heron Therapeutics (HRTX) received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. The company has until December 22, 2026, to regain compliance by maintaining a share price above $1.00 for ten consecutive days. Failure to do so may lead to delisting proceedings. While shares continue trading, this uncertainty could impact capital access. Analysts maintain a Buy rating with a $2.00 target, though AI analysis cites weak financials and technical downtrends."
datetime: "2026-06-25T21:36:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290883269.md)
  - [en](https://longbridge.com/en/news/290883269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290883269.md)
---

# Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency

Heron Therapeutics ( (HRTX) ) has provided an announcement.

On June 25, 2026, Heron Therapeutics disclosed that it had received a notice from Nasdaq stating its common stock failed to meet the $1.00 minimum bid price requirement over the 30 trading days from May 12 to June 24, 2026. The company now has until December 22, 2026, an initial 180-day period, to regain compliance by lifting its share price to at least $1.00 for a minimum of ten consecutive trading days.

Heron’s shares will continue to trade on the Nasdaq Capital Market under the HRTX ticker during this period, with no immediate impact on listing status while the company monitors its stock price and evaluates options to restore compliance. If it cannot meet the requirement within the first window, Heron may qualify for an additional 180-day extension, but failure to ultimately cure the deficiency could result in delisting proceedings, heightening uncertainty for investors and potentially constraining future capital access.

The most recent analyst rating on (HRTX) stock is a Buy  
with a $2.00 price target.  
To see the full list of analyst forecasts on Heron Therapeutics stock,  
see the HRTX Stock Forecast page.

**Spark’s Take on HRTX Stock**

According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.

The score is held down primarily by weak financial strength (ongoing losses and negative free cash flow, plus very high leverage and a thin equity cushion) and a strong technical downtrend with oversold momentum. Offsetting these, the latest earnings call was constructive with reaffirmed 2026 guidance and product-demand momentum, but near-term margin pressure and execution/funding risk keep the overall score below average.

To see Spark’s full report on HRTX stock,  
click here.

**More about Heron Therapeutics**

Heron Therapeutics, Inc. is a biopharmaceutical company whose common shares trade on The Nasdaq Capital Market under the symbol HRTX. The company operates within the healthcare and life sciences sector, relying on continued access to public equity markets for funding its operations and advancing its therapeutic pipeline.

**Average Trading Volume:** 3,101,201

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $79.23M

### Related Stocks

- [HRTX.US](https://longbridge.com/en/quote/HRTX.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty](https://longbridge.com/en/news/295405345.md)
- [Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday](https://longbridge.com/en/news/294710967.md)
- [Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook](https://longbridge.com/en/news/295404922.md)
- [Heron Therapeutics amends Hercules Capital credit facility, cuts principal by $13.5 million](https://longbridge.com/en/news/295403890.md)
- [Mobimo places CHF 100 million green bond on Swiss capital market](https://longbridge.com/en/news/295557288.md)